- Leadership is pleased with the above market growth but noted that performance was below expectations, particularly for distributors; as a result, the company walked back its previous 2019 outlook and now expects to grow in the 8% to 10% range
- Hand and wrist products continued their solid performance, but lower extremity products did not perform to expectations
- Distributors in Europe held back from investing in sets due to uncertainty around the EU’s Medical Device Regulation
- Medartis is investing in sterile disposable packaging in anticipation of increased demand in Europe
- Australian sales were impacted by a 7% nation-wide reduction in reimbursement, while seasonal slowdowns affected sales in Japan
Performance by Segment
ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows ($MM):
1H19 | 1H18 | $ Chg | % Chg | |
Trauma | $59.0 | $55.8 | $3.2 | 5.7% |
Other (CMF) | $5.8 | $5.5 | $0.3 | 6.3% |
Total | $64.8 | $61.3 | $3.5 | 5.7% |
Sales by Geographic Region
ORTHOWORLD estimates geographic sales and growth as follows ($MM):
1H19 | 1H18 | $ Chg | % Chg | |
US | $10.8 | $9.3 | $1.4 | 15.1% |
Ex-US | $54.1 | $51.9 | $2.1 | 4.1% |
EMEA | $34.9 | $34.2 | $0.7 | 2.1% |
Asia Pacific | $11.6 | $11.3 | $0.3 | 2.7% |
Rest of World | $7.6 | $6.5 | $1.1 | 16.9% |
Total | $64.8 | $61.3 | $3.5 | 5.7% |
Sources: Medartis; ORTHOWORLD estimates.
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
Leadership is pleased with the above market growth but noted that performance was below expectations, particularly for distributors; as a result, the company walked back its previous 2019 outlook and now expects to grow in the 8% to 10% range
Hand and wrist products continued their solid performance, but lower extremity...
- Leadership is pleased with the above market growth but noted that performance was below expectations, particularly for distributors; as a result, the company walked back its previous 2019 outlook and now expects to grow in the 8% to 10% range
- Hand and wrist products continued their solid performance, but lower extremity products did not perform to expectations
- Distributors in Europe held back from investing in sets due to uncertainty around the EU’s Medical Device Regulation
- Medartis is investing in sterile disposable packaging in anticipation of increased demand in Europe
- Australian sales were impacted by a 7% nation-wide reduction in reimbursement, while seasonal slowdowns affected sales in Japan
Performance by Segment
ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows ($MM):
1H19 | 1H18 | $ Chg | % Chg | |
Trauma | $59.0 | $55.8 | $3.2 | 5.7% |
Other (CMF) | $5.8 | $5.5 | $0.3 | 6.3% |
Total | $64.8 | $61.3 | $3.5 | 5.7% |
Sales by Geographic Region
ORTHOWORLD estimates geographic sales and growth as follows ($MM):
1H19 | 1H18 | $ Chg | % Chg | |
US | $10.8 | $9.3 | $1.4 | 15.1% |
Ex-US | $54.1 | $51.9 | $2.1 | 4.1% |
EMEA | $34.9 | $34.2 | $0.7 | 2.1% |
Asia Pacific | $11.6 | $11.3 | $0.3 | 2.7% |
Rest of World | $7.6 | $6.5 | $1.1 | 16.9% |
Total | $64.8 | $61.3 | $3.5 | 5.7% |
Sources: Medartis; ORTHOWORLD estimates.
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.